Medtronic IP Litigation Head Led Patent Defense Efforts

The medical device giant relies on an extensive patent portfolio as its intellectual property team manages high-stakes litigation.

Updated on Sept. 28, 2026 in Healthcare

Isometric editorial illustration of a complex, monolithic geometric structure standing in a wide field, representing organizational strategy. — Medtronic’s legal team manages a massive patent portfolio of over 43,000 active patents to protect its long-term medical device research and development cycles. AI Illustration. Upload story photo >

Live Poll

Is aggressive patent enforcement necessary to ensure the development of new medical technologies?

Mark Blake oversees intellectual property litigation for Medtronic, which manages a massive portfolio of over 43,000 active patents. This strategy protects the company's investments across its 20 diverse business units.

Why it matters

Intellectual property protection is essential for Medtronic to secure the significant capital and research investments required during the lengthy three-to-five-year development cycle for new medical devices.

Medtronic holds more than 43,000 active patents across 20 distinct business units, including a neuroscience segment that generates over $10 billion in annual revenue. The company recently secured FDA clearance for its LigaSure RAS Maryland device.

The players

Mark Blake

He serves as the head of intellectual property litigation for Medtronic and oversees the legal defense of the company's extensive patent portfolio.

Medtronic

Headquartered in Minnesota, this global medical device company develops healthcare technologies and holds thousands of active patents.

Brett Wall

He previously served as the leader of the Medtronic neuroscience unit, which generates over $10 billion in annual revenue.

Federal Circuit

This appellate court reviews patent cases and issued a finding of non-infringement in the Colibri Heart Valve LLC case.

The details

Dedicated legal teams handle intellectual property for each of Medtronic's business units, ensuring that multi-year product development remains protected under federal law. This legal infrastructure supported the company last July when the Federal Circuit reversed a $125 million patent infringement judgment in the Colibri Heart Valve LLC case.

In July 2025, the Federal Circuit reversed a $125 million patent infringement judgment against Medtronic.
Brett Wall stepped down from his leadership role in the neuroscience unit in June 2026.
Medtronic received FDA clearance for the LigaSure RAS Maryland device in August 2026.
Brett Wall will serve as the keynote speaker at a Business Journal award event on October 7, 2026.

Market Landscape

The reversal in the Colibri Heart Valve LLC case establishes a critical legal precedent for how the Federal Circuit evaluates patent infringement claims against large medical device manufacturers. This judicial outcome reinforces the protective barrier Medtronic maintains around its $10 billion neuroscience segment.

For patients and healthcare providers, the protection of Medtronic's intellectual property ensures that the company can continue to fund and bring new devices like the LigaSure RAS Maryland to market. These legal and regulatory milestones help maintain the consistent availability of advanced medical tools across the company's various business units.

The takeaway

Medtronic utilizes a highly specialized legal structure to safeguard the massive investments required to bring complex medical technology to patients. This rigorous approach to intellectual property management remains a core component of the company's long-term business strategy.